H19 is a significantly down-regulated lncRNA in prostate cancer confirmed to inhibit the invasion of tumor cells by targeting TGFBI via regulating miR-675, which could be a biomarker to benefit diagnosis and therapy of advanced prostate cancer (Zhu et al., 2014). This evidence concerns the gene H19 and prostate carcinoma.